Unveiling Antibiotic Resistance in Ventilator-Associated Pneumonia Patients: A Comprehensive Analysis

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Microbiology

Background:

• Ventilator-associated pneumonia (VAP) is a significant healthcare-associated infection, particularly in resource-limited settings with prevalent multidrug-resistant organisms.
• Assessing the bacteriological profile and antimicrobial susceptibility of endotracheal aspirates is crucial for VAP management.

Purpose of the Study:

• To determine the bacteriological profile and antimicrobial susceptibility patterns of endotracheal aspirates in VAP patients.
• To compare microbial distribution between early-onset and late-onset VAP.

Main Methods:

• A descriptive cross-sectional study included adult patients mechanically ventilated for over 48 hours with suspected VAP (CPIS score >6).
• Endotracheal aspirates were cultured semi-quantitatively (≥10⁵ CFU/mL significant), and antimicrobial susceptibility testing was performed.
• Demographic data, risk factors, isolates, and resistance patterns were analyzed using chi-square tests.

Main Results:

• VAP incidence was 32.7% (195/596 patients), with an incidence density of 33.6 per 1000 ventilator-days.
• Gram-negative pathogens predominated (76.1% early vs. 78% late VAP), with Acinetobacter baumannii being the most common isolate.
• Extensive multidrug resistance was observed; only polymyxin B and colistin showed universal susceptibility. Carbapenem susceptibility varied, with higher sensitivity in late-onset A. baumannii.

Conclusions:

• The high burden of VAP is driven by multidrug-resistant Gram-negative organisms, especially Acinetobacter baumannii and Klebsiella pneumoniae.
• Strengthened antimicrobial stewardship, resistance surveillance, and VAP prevention bundles are urgently needed.
• Early culture-guided de-escalation is essential for optimizing patient outcomes and controlling antimicrobial resistance.